Noninvasive Cancer Diagnostics: Technologies and Global Markets

Noninvasive Cancer Diagnostics: Technologies and Global Markets

Aug 2017 BCC Research Healthcare335 Pages Price :
$ $4950

The global market for noninvasive cancer diagnostics was valued at $107.4 billion in 2016. This market is estimated to grow from nearly $114.6 billion in 2017 to $159.8 billion by 2022 with a compound annual growth rate (CAGR) of 6.9% for the period of 2017-2022.
Diagnostic imaging technologies, the leading segment of this market, will grow from $43.6 billion in 2017 to $58.5 billion by 2022 with a CAGR of 6.1%.
The market for advanced noninvasive approaches will grow from $40.5 billion in 2017 to $57.9 billion by 2022 with a CAGR of 7.4%.

##img_0##
Table of Contents
Chapter 1: Introduction - 1
Study Goals and Objectives- 2
Scope of Report - 2
Methodology and Information Sources - 3
Primary Data and Information Gathering - 3
Secondary Data and Information Gathering - 4
Market Share Analysis and Market Forecast Prediction - 4
Geographic Breakdown - 5
Analyst's Credentials - 9
Related BCC Research Reports- 9
Chapter 2: Summary and Highlights - 11
Summary of Key Findings - 11
Diagnostic Imaging Segment - 13
Advanced Diagnostics Segment - 13
Conventional Segment - 14
Chapter 3: Market and Technology Review: Diagnostic Imaging - 16
Real-time In Vivo Cancer Diagnosis using Raman Spectroscopy - 16
In-Vivo Fluorescence Imaging in Personalized Cancer Diagnostics - 18
Direct Imaging - 18
Indirect Fluorescence Imaging - 19
Magnetic Resonance Imaging (MRI) Scans - 19
Development to the RF Subsystem - 22
Positron Emission Tomography (PET) Scan - 26
Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) - 29
Mammography - 31
Digital Mammography Systems - 32
Breast Tomosynthesis Systems - 35
Ultrasound - 36
Barium Swallow or Enema - 41
Bone Scans (MRI, CT and PET) - 42
Market Estimate - 42
Chapter 4: Market and Technology Review: Advanced Noninvasive Cancer
Diagnostic Assays and Technologies - 44
Introduction to Circulating Nucleic Acids (CNAs) - 46
Circulating Nucleic Acids as a Diagnostic Tool - 49
Circulating DNA as a Biomarker of Cancer - 50
Use of Circulating DNA for Prenatal Diagnosis (Conventional) - 50
Use of Circulating DNA for Prenatal Diagnosis (Noninvasive) - 51
Circulating RNA as a Biomarker of Cancer - 51
Methods Used for the Detection of Circulating Nucleic Acids - 55
Liquid Biopsy - 56
Janssen Diagnostics - 58
Roche Molecular Systems Inc. - 59
Genomic Health - 59
Foundation Medicine - 60
Veracyte - 60 -
Trovagene Inc. - 60
Myriad Genetics - 61
OncoCyte Corp. - 61
Illumina - 61
NeoGenomics Laboratories - 62
Biocept Inc. - 62
Vermillion Inc. - 63
Sysmex Inostics, a subsidiary of Sysmex Corp. - 63
Guardant Health - 63
Product Development and New Initiatives in Liquid Biopsy - 63
Molecular Cytogenetic/Gene Expression Studies - 65
Amplify and Detect Diminished Amounts of RNA Consistently - 68
Analyze Hundreds of Genes - 69
Proteomics and New Protein Markers - 69
Inside the ProteinChip System - 70
Proteome Pattern Recognition - 71
Next-Generation Sequencing (NGS) Studies - 72
Illumina Solexa System - 73
Roche 454 Sequencing - 73
Thermo Fisher Scientific Ion Personal Genome Machine (PGM) - 74
Thermo Fisher Scientific SOLiD (Sequencing by Oligonucleotide Ligation and Detection) - 74
Oxford Nanopore Technologies - 75
The Third-Generation Sequencer - 75
Clinical Acceptance of a New Diagnostic Assay - 76
Saliva-Based Oral Cancer Diagnostics - 78
Advanced Tissue Staining (Immunohistochemistry (IHC) and in situ Hybridization (ISH)) - 79
Optical Biopsy - 80
Market Estimate - 81
Chapter 5: Market and Technology Review: Conventional Noninvasive Cancer
Diagnostic Assays and Tests - 83
Pap Test and HPV Testing - 84
Tumor Biomarker Testing - 86
MammaPrint Specifications - 92
Genomic Healths Oncotype DX Breast Cancer Test - 93
The Prosigna Breast Cancer Prognostic Gene Signature Assay (formerly called the PAM50 test) - 94
Sales and Marketing Strategies for Cancer Tests - 95
Fecal Occult Blood Tests (FOBT) - 97
Digital Rectal Exam (DRE) - 100
Multigated Acquisition (MUGA) Scans - 100
Market Estimate - 101
Chapter 6: Incidence, Prevalence and Mortality Statistics for Cancer: A Global
Summary - 103
Cancer: The Disease - 103
Cancer: A Statistical Analysis of the Disease Incidence and Prevalence - 104
Incidence and Prevalence Rates for Major Cancer Types - 104
Regional Patterns of Cancer - 113
Europe - 113
North America - 113
Asia-Pacific- 115
Latin and Central America - 116
Middle East/Africa - 116
The Global Cancer Burden and Worldwide Cancer Risk Factors - 117
Tobacco Use and Statistics - 117
Alcohol Abuse and Cancer Statistics - 118
Obesity and Cancer Statistics - 118
Infectious Diseases and Cancer - 118
Inherited Genes/Diseases and Cancer - 119
Sun, U.V. and Cancer - 120
Hormones and Cancer - 120
Chapter 7: Noninvasive Cancer Diagnostics Market by Cancer Type - 122
Global Noninvasive Cancer Diagnostics Market, by Cancer Type - 122
Global Market Drivers - 127
Global Market Restraints - 131
Regional Noninvasive Cancer Diagnostics Market Assessment: North America - 133
Selected Market Drivers: North America - 133
Selected Market Restraints: North America - 136
Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type - 138
Regional Noninvasive Cancer Diagnostics Market Assessment: Europe - 140
Selected Market Drivers: Europe - 141
Selected Market Restraint: Europe - 143
Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type - 144
Regional Noninvasive Cancer Diagnostics Market Assessment: Asia-Pacific - 152
Selected Market Drivers: Asia-Pacific - 153
Selected Market Restraints: Asia-Pacific - 157
Regional Noninvasive Cancer Diagnostics Market Assessment: Central and Latin America - 162
Selected Market Drivers: Central and Latin America - 163
Selected Market Restraints: Central and Latin America - 166
Regional Noninvasive Cancer Diagnostics Market Assessment: Middle East/Africa - 171
Selected Market Drivers: Middle East/Africa - 174
Selected Market Restraints: Middle East/Africa - 175
Chapter 8: Market Analysis by Technology, End User and Market Share - 179
Global Noninvasive Cancer Diagnostics Market, by Technology - 179
Regional Noninvasive Cancer Diagnostics Market, by Technology: North America - 183
Regional Noninvasive Cancer Diagnostics Market, by Technology: Europe - 186
Regional Noninvasive Cancer Diagnostics Market, by Technology: Asia-Pacific - 189
Regional Noninvasive Cancer Diagnostics Market, by Technology: Central and Latin America - 191
Regional Noninvasive Cancer Diagnostics Market, by Technology: Middle East/Africa - 194
Global Noninvasive Cancer Diagnostics Market, by End-User - 196
General Clinical Reference Laboratories - 199
Market Share Analysis by Technology: Noninvasive Cancer Diagnostics Market - 200
Chapter 9: Technological Advances, Trends and Opportunities - 211
Key Technological Developments and Advances, Market Trends and Opportunities - 211
Developments and Advances, Trends and Opportunities in Diagnostic Imaging - 211
Developments and Advances, Trends and Opportunities in Advanced Noninvasive Approaches - 214
Developments and Advances, Trends and Opportunities in Screening Assays - 217
Opportunities for IVDMIA Companies - 220
Chapter 10: Regulatory and Legislative Requirements - 223
United States - 223
How are IVDs Classified? - 223
FDA Regulations Relating to Companion Diagnostics - 226
Laboratory Developed Tests (LDTs) - 227
Centers for Medicare & Medicaid Services (CMS) - 228
The 2010 Affordable Care Act - 229
Private Insurance - 229
Europe - 231
(General) Medical Device Directive, MDD (93/42/EEC) - 232
Active Implantable Medical Device Directive, AIMDD (90/383/EEC - 233
In Vitro Diagnostic Medical Device Directive, IVDMDD (98/79/EC) - 234
Proposal for Changes to the Medical Device Directive, MDD (93/42/EEC) - 234
Japan - 236
Marketing Authorization System - 237
China - 239
Overview of the Healthcare System - 239
Healthcare Reforms - 241
Healthcare Institutions - 241
India - 245
Overview of the Healthcare System - 245
Hospital Resources - 248
Population Statistics - 249
South Korea - 250
Brazil - 251
Background - 251
Regulatory and Legislative Requirements - 253
Market Entry and Reimbursement of Medical Devices: Brazil- 254
Argentina- 255
Background - 255
Government-funded Public Health Sector - 256
Social Health Insurance Sector - 256
Private Sector - 257
Regulatory and Legislative Requirements - 257
Mexico - 258
Legislation and Regulations Governing Medical Devices in Mexico - 259
Health Insurance Structure in Mexico - 260
Chapter 11: Patent Review of Key Technologies - 262
Microarray Patents - 263
LOAC Patents- 268
Clinical Next-Generation Sequencing (NGS) Patents - 270
Clinical NGS Patents Summary - 270
Clinical NGS Patents by Indication- 272
Chapter 12: Company Profiles - 275
Appendix A: Company Addresses and Contact Details - 335
Appendix B: Government Regulatory Agencies and Professional Organizations 349
Appendix C: Commonly Used Acronym Associated with Noninvasive Cancer
Diagnostics - 354
About BCC Research - 365
About BCC Research- 366
BCC Membership - 366
BCC Custom Research - 366

List of Table

List of Tables
Summary Table Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($
Millions) - 12
Table 1 Diagnostic Imaging Segment - 13
Table 2 Advanced Segment - 14
Table 3 Conventional Segment - 14
Table 4 Noninvasive Cancer Diagnostics Market Segmentation - 16
Table 5 Breast MRI Systems Currently Available - 20
Table 6 Wide Bore MRI Systems Currently Available - 21
Table 7 PET/CT Systems Currently Available - 27
Table 8 PET/MR Systems Currently Available - 31
Table 9 Key trends in (Digital Mammography Systems) - 33
Table 10 Digital Mammography Systems Currently Available - 33
Table 11 Breast Tomosynthesis Systems Currently Available - 36
Table 12 Benefits of Medical Ultrasound Imaging - 37
Table 13 Regulatory Approval for High-intensity Focused Ultrasound (HIFU) by Region - 38
Table 14 Ultrasound Systems Currently Available - 39
Table 15 Noninvasive Cancer Diagnostics Market Segmentation - 45
Table 16 Major Developments in Understanding Nucleic Acids and their Cellular Roles - 47
Table 17 Circulating Tumor-associated miRNAs as Potential Cancer Biomarkers - 52
Table 18 Key Elements for Business Competition in Gene Expression Profiling for Cancer - 65
Table 19 DNA Microarray Diagnostic Test Adoption Rate - 76
Table 20 Characteristics of in situ Hybridization Methods - 80
Table 21 Key Advantages of Optical Biopsy Systems - 81
Table 22 Noninvasive Cancer Diagnostics Market Segmentation - 84
Table 23 Key Drivers to Adoption of Biomarkers in Clinical Use - 88
Table 24 Key Barriers to Adoption of Biomarkers in Clinical Use - 88
Table 25 Tumor Biomarkers Currently in Common Clinical Use - 89
Table 26 MammaPrint: Key Features- 93
Table 27 Strategies for Marketing Cancer Diagnostic Products - 96
Table 28 Advantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT)) - 98
Table 29 Disadvantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT)) . 98
Table 30 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence, 2012 105
Table 31 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (In Men
and Women Combined) by Cancer Type, 2012 - 106
Table 32 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (Men) by
Cancer Type, 2012 - 109
Table 33 Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (Women)
by Cancer Type, 2012 - 111
Table 34 Estimated Number of New Cancer Cases by Sex: United States, 2017 (%) - 114
Table 35 Estimated Number of Deaths from Cancer by Sex: United States, 2017 - 115
Table 36 Global Noninvasive Cancer Diagnostics Market, Through 2022 ($ Millions) - 122
Table 37 Global Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) . 123
Table 38 Global Noninvasive Cancer Diagnostics Market and Market Share, by Cancer Type, 2017 (%)
- 124
Table 39 Global Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%) - 126
Table 40 North American Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 134
Table 41 Sample Listing of Payers that Published Positive Coverage Policies for KRAS Testing - 135
Table 42 United States Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 138
Table 43 Canada Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) 140
Table 44 European Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
- 141
Table 45 Europe: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%) - 142
Table 46 France Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) 145
Table 47 Germany Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
- 146
Table 48 Italy Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) - 147
Table 49 Spain Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) - 148
Table 50 U.K. Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) - 149
Table 51 Benelux Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
- 150
Table 52 Scandinavia Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 151
Table 53 Rest of Europe Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 152
Table 54 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 153
Table 55 Asia-Pacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%) - 154
Table 56 China: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) - 160
Table 57 India: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 ($ Millions) - 160
Table 58 Japan: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 ($ Millions) - 161
Table 59 South Korea: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 161
Table 60 Rest of Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 162
Table 61 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through
2022 ($ Millions) - 163
Table 62 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%) ..... 164
Table 63 Argentina: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
- 168
Table 64 Brazil: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) .. 169
Table 65 Chile: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) ... 169
Table 66 Mexico: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)170
Table 67 Rest of Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type,
Through 2022 ($ Millions) - 171
Table 68 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 172
Table 69 Middle East/Africa: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%) ....... 173
Table 70 Middle East: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($
Millions) - 176
Table 71 Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions) . 177
Table 72 Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions) ... 180
Table 73 Global Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through
2022 ($ Millions) - 181
Table 74 Global Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies,
Through 2022 ($ Millions) - 182
Table 75 Global Noninvasive Cancer Diagnostics Market, by Conventional Noninvasive Cancer Screening
and Diagnostic Assays and Tests Technology, Through 2022 ($ Millions) - 182
Table 76 North America: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($
Millions) - 183
Table 77 North American: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies,
Through 2022 ($ Millions) - 184
Table 78 North American: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive
Technologies, Through 2022 ($ Millions) - 185
Table 79 North American: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology,
Through 2022 ($ Millions) - 185
Table 80 Europe: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions) . 186
Table 81 Europe: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through
2022 ($ Millions) - 187
Table 82 Europe: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies,
Through 2022 ($ Millions) - 188
Table 83 Europe: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through
2022 ($ Millions) - 188
Table 84 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($
Millions) - 189
Table 85 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies,
Through 2022 ($ Millions) - 190
Table 86 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies,
Through 2022 ($ Millions) - 190
Table 87 Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through
2022 ($ Millions) - 191
Table 88 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Technology, Through
2022 ($ Millions) - 192
Table 89 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging
Technologies, Through 2022 ($ Millions) - 192
Table 90 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive
Technologies, Through 2022 ($ Millions) - 193
Table 91 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Screening Assay
Technology, Through 2022 ($ Millions) - 193
Table 92 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($
Millions) - 194
Table 93 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging
Technologies, Through 2022 ($ Millions) - 195
Table 94 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive
Technologies, Through 2022 ($ Millions) - 195
Table 95 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology,
Through 2022 ($ Millions) - 196
Table 96 Global Noninvasive Cancer Diagnostics Market, by End-User, Through 2022 ($ Millions) - 197
Table 97 Global Market Share for Diagnostic Imaging, Noninvasive Cancer Diagnostics, by Company,
2017 (%) - 201
Table 98 Global Market Share for Advanced Noninvasive Approaches, Noninvasive Cancer Diagnostics,
by Company, 2017 (%) - 202
Table 99 Global Market Share for Molecular Signature-Based Noninvasive Cancer Diagnostics, by
Company, 2017 (%) - 203
Table 100 Global Market Share for DNA Microarray-Based Noninvasive Cancer Diagnostics, by Company,
2017 (%) - 204
Table 101 Global Market Share for Cytogenetic/Gene Expression-Based Noninvasive Cancer Diagnostics,
by Company, 2017 (%) - 205
Table 102 Global Market Share for Circulating Nucleic Acid (CNA)-Based Noninvasive Cancer
Diagnostics, by Company, 2017 (%) - 206
Table 103 Global Market Share for Screening Assays, Noninvasive Cancer Diagnostics, by Company,
2017 (%) - 207
Table 104 Global Market Share for Fecal Occult Blood Test (FOBT)-Based Noninvasive Cancer
Diagnostics, by Company, 2017 (%) - 208
Table 105 Global Market Share for Tumor Biomarker Test-Based Noninvasive Cancer Diagnostics, by
Company, 2017 (%) - 209
Table 106 Principal Factors Influencing the Growth and Development of Noninvasive Cancer
Diagnostics, 2017 - 212
Table 107 Uses of Tumor Biomarkers in Drug Development - 219
Table 108 Utility of Biomarkers as Companion Diagnostics to Drug Development - 220
Table 109 Overview of Pharmaceutical Affair Law (PAL) and Japanese Medical Device Nomenclature
(JMDN) Codes and Related Codes according to the EU MDD - 237
Table 110 Number of Healthcare Institutions According to Ownership in China, 2010 - 242
Table 111 Total Number of Hospitals by Ranking in China, 2010 - 243
Table 112 Overview of Healthcare in India - 246
Table 113 DNA Microarray Patents by Region, 2002-2012 - 263
Table 114 Microarray-Related Proteomics Patents by Region, 2002 2012 - 264
Table 115 Microarray-Related Patents by Application and Title, 2017 - 264
Table 116 Patent Application and Title: Noninvasive Cancer Diagnostics, 2001 Present- 266
Table 117 LOAC-Related Proteomics Patents by Region, 2002 2012 - 269
Table 118 LOAC-Related Patents by Application and Title, 2013 2015 - 269
Table 119 Clinical Next Generation Sequencing Patents, 20022012 - 270
Table 120 Clinical NGS-Related Patents by Application and Title, 2013 2015 - 271
Table 121 Clinical NGS Patents by Indication, 20022012 - 272
Table 122 Abbott Laboratories: Company Financials, Through 2016 ($ Millions) - 278
Table 123 Bayer AG: Company Financials, Through 2016 ($ Millions) - 284
Table 124 bioMerieux S.A. Sales by Application, Through 2016 ($ Millions) - 289
Table 125 Exact Sciences Corp.: Company Financials, Through 2016 ($ Millions/%) - 295
Table 126 Hologic Inc.: Company Financials, 2015-2016 ($ Millions) - 302
Table 127 Illumina, Inc: Company Financials, 2014-2016 ($ Millions) - 305
Table 128 Myriad Genetics Inc. Financials, 2014 - 2016 ($ Millions) - 309
Table 129 Philips Healthcare Financials, Through 2016 ($ Millions) - 313
Table 130 Philips Group Financials by Segment, 2016 ($ Millions) - 314
Table 131 Qiagen N.V. Financials, Through 2016 ($ Millions) - 316
Table 132 Qiagen N.V. Financials by Region, Through 2016 ($ Millions) - 316
Table 133 Quest Diagnostics Financials, Through 2016 ($ Millions) - 320
Table 134 Roche Group Financials, Through 2016 ($ Millions) - 322 -
Table 135 Diagnostics Division Financials, 2015 and 2016 ($ Millions) - 322
Table 136 Thermo Fisher Scientific Inc. Financials, Through 2016 ($ Millions) - 330
Table 137 Company Addresses and Contact Details- 335
Table 138 Government Regulatory Agencies and Professional Organizations Associated with
Noninvasive Cancer Diagnostics - 349
Table 139 Commonly Used Acronym Associated with Noninvasive Cancer Diagnostics - 354

List of Chart

List of Figures
Summary Figure Global Noninvasive Cancer Diagnostics Market, by Technology, 2016-2022 ($ Millions)
- 12
Figure 1 Top Molecular CNA Characterization Techniques (%) - 57
Figure 2 Market Growth and Evolution of MDx Cancer Biomarkers - 95
Figure 3 Estimated Global Cancer Incidence Proportions by Major Sites, In Men and Women Combined,
2012 (%) - 108
Figure 4 Estimated World Cancer Incidence Proportions by Major Sites, In Men, 2012 (%) - 110
Figure 5 Estimated World Cancer Incidence Proportions by Major Sites, In Women, 2012 (%) - 112
Figure 6 Global Market Share for Noninvasive Cancer Diagnostics, by Cancer Type, 2017 (%) - 125
Figure 7 Global Noninvasive Cancer Diagnostics Market, by Region, 2017 (%) - 126
Figure 8 Average Number of New Cases per Year and Age-Specific Incidence Rates for all Cancers in the
U.K., 20122014 - 129
Figure 9 Europe: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%) - 142
Figure 10 Asia-Pacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%) - 154
Figure 11 Central and Latin America: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
- 165
Figure 12 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%) - 173
Figure 13 Global Noninvasive Cancer Diagnostics Market, by Technology Type, 2016-2022 ($ Millions)
- 180
Figure 14 Global Noninvasive Cancer Diagnostics Market, by End-User, 2016-2022 ($ Millions) - 198
Figure 15 Tumor Biomarker Developments and Market Applications (%) - 218
Figure 16 Private Health Insurance Coverage among Persons Under 65 in United States, 20072011
(Millions/Percent) - 231
Figure 17 The Chinese Healthcare System - 240

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ $4950
$ $7128

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top